Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Corcept Therapeutics Incorporated is a biotechnology business based in the US. Corcept Therapeutics Incorporated shares (CORT) are listed on the NASDAQ and all prices are listed in US Dollars. Corcept Therapeutics Incorporated employs 236 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$11.91 - $31.18|
|50-day moving average||$24.44|
|200-day moving average||$23.64|
|Wall St. target price||$27.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.85|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Corcept Therapeutics Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Corcept Therapeutics Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Corcept Therapeutics Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 27x. In other words, Corcept Therapeutics Incorporated shares trade at around 27x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Corcept Therapeutics Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Corcept Therapeutics Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Corcept Therapeutics Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $128.7 million.
The EBITDA is a measure of a Corcept Therapeutics Incorporated's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$353.9 million|
|Operating margin TTM||36.23%|
|Gross profit TTM||$348.3 million|
|Return on assets TTM||16.28%|
|Return on equity TTM||23.7%|
|Market capitalisation||$2.7 billion|
TTM: trailing 12 months
There are currently 10.5 million Corcept Therapeutics Incorporated shares held short by investors – that's known as Corcept Therapeutics Incorporated's "short interest". This figure is 2.9% down from 10.8 million last month.
There are a few different ways that this level of interest in shorting Corcept Therapeutics Incorporated shares can be evaluated.
Corcept Therapeutics Incorporated's "short interest ratio" (SIR) is the quantity of Corcept Therapeutics Incorporated shares currently shorted divided by the average quantity of Corcept Therapeutics Incorporated shares traded daily (recently around 571917.86885246). Corcept Therapeutics Incorporated's SIR currently stands at 18.3. In other words for every 100,000 Corcept Therapeutics Incorporated shares traded daily on the market, roughly 18300 shares are currently held short.
However Corcept Therapeutics Incorporated's short interest can also be evaluated against the total number of Corcept Therapeutics Incorporated shares, or, against the total number of tradable Corcept Therapeutics Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Corcept Therapeutics Incorporated's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Corcept Therapeutics Incorporated shares in existence, roughly 90 shares are currently held short) or 0.1162% of the tradable shares (for every 100,000 tradable Corcept Therapeutics Incorporated shares, roughly 116 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Corcept Therapeutics Incorporated.
Find out more about how you can short Corcept Therapeutics Incorporated stock.
We're not expecting Corcept Therapeutics Incorporated to pay a dividend over the next 12 months.
Over the last 12 months, Corcept Therapeutics Incorporated's shares have ranged in value from as little as $11.91 up to $31.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corcept Therapeutics Incorporated's is 0.7628. This would suggest that Corcept Therapeutics Incorporated's shares are less volatile than average (for this exchange).
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California. .
Everything we know about the Talaris Therapeutics IPO, plus information on how to buy in.
Everything we know about the Sagimet Biosciences IPO, plus information on how to buy in.
Everything we know about the Zenvia IPO, plus information on how to buy in.
Everything we know about the Grove IPO, plus information on how to buy in.
Everything we know about the Pasithea Therapeutics IPO, plus information on how to buy in.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.